SATB2 Suppresses Non-small Cell Lung Cancer Invasiveness by G9a

Overview

Journal Clin Exp Med

Specialty General Medicine

Date 2017 Jul 2

PMID 28667416

Citations 17

Authors

Yi-Nan Ma

Hai-Yan Zhang

Liang-Ru Fei

Mei-Yu Zhang

Cong-Cong Wang

Yuan Luo

Yu-Chen Han

Affiliations

Soon will be listed here.

Abstract

Special AT-rich sequence-binding protein 2 (SATB2) is a transcription factor, which plays an important role in transcriptional regulation and chromatin recombinant by combining with matrix attachment regions. More evidence shows that SATB2 is involved in progression of breast cancer, head and neck squamous cell carcinomas and osteosarcoma. However, the role of SATB2 in cancer initiation and progression is still not well understood. Our study identified that decreased expression of SATB2 was correlated with tumor progression and poor prognosis in non-small cell lung cancer (NSCLC) patients. Furthermore, SATB2 suppressed lung cancer cell invasion and metastasis and regulated the expression of EMT-related proteins and histone methylation by G9a. In summary, SATB2 may act as a tumor suppressor gene in NSCLC.

Citing Articles

Oncogenic Role of SATB2 In Vitro: Regulator of Pluripotency, Self-Renewal, and Epithelial-Mesenchymal Transition in Prostate Cancer.

Yu W, Srivastava R, Srivastava S, Ma Y, Shankar S, Srivastava R Cells. 2024; 13(11.

PMID: 38891096 PMC: 11171950. DOI: 10.3390/cells13110962.

Anti-cancer targets and molecular mechanisms of formononetin in treating osteosarcoma based on network pharmacology.

Chen L, Zhou Y, Weng Z, Liu S, Li T, Wang Y Aging (Albany NY). 2023; 15(20):11489-11507.

PMID: 37870753 PMC: 10637808. DOI: 10.18632/aging.205139.

Identification of a novel gene signature of lung adenocarcinoma based on epidermal growth factor receptor-tyrosine kinase inhibitor resistance.

Zhou E, Wu F, Guo M, Yin Z, Li Y, Li M Front Oncol. 2022; 12:1008283.

PMID: 36530971 PMC: 9751970. DOI: 10.3389/fonc.2022.1008283.

The Molecular and Cellular Strategies of Glioblastoma and Non-Small-Cell Lung Cancer Cells Conferring Radioresistance.

Alhaddad L, Osipov A, Leonov S Int J Mol Sci. 2022; 23(21).

PMID: 36362359 PMC: 9656305. DOI: 10.3390/ijms232113577.

Potential Therapeutics Targeting Upstream Regulators and Interactors of EHMT1/2.

Ang G, Gupta A, Surana U, Yap S, Taneja R Cancers (Basel). 2022; 14(12).

PMID: 35740522 PMC: 9221123. DOI: 10.3390/cancers14122855.

References

Britanova O, de Juan Romero C, Cheung A, Kwan K, Schwark M, Gyorgy A . Satb2 is a postmitotic determinant for upper-layer neuron specification in the neocortex. Neuron. 2008; 57(3):378-92. DOI: 10.1016/j.neuron.2007.12.028. View

Zhong X, Chen X, Guan X, Zhang H, Ma Y, Zhang S . Overexpression of G9a and MCM7 in oesophageal squamous cell carcinoma is associated with poor prognosis. Histopathology. 2014; 66(2):192-200. DOI: 10.1111/his.12456. View

Dong C, Wu Y, Yao J, Wang Y, Yu Y, Rychahou P . G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J Clin Invest. 2012; 122(4):1469-86. PMC: 3314447. DOI: 10.1172/JCI57349. View

Wozniak R, Klimecki W, Lau S, Feinstein Y, Futscher B . 5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene. 2006; 26(1):77-90. DOI: 10.1038/sj.onc.1209763. View

Bengani H, Handley M, Alvi M, Ibitoye R, Lees M, Lynch S . Clinical and molecular consequences of disease-associated de novo mutations in SATB2. Genet Med. 2017; 19(8):900-908. PMC: 5548934. DOI: 10.1038/gim.2016.211. View

Yang M, Yu J, Jiang D, Li W, Wang S, Ding Y . microRNA-182 targets special AT-rich sequence-binding protein 2 to promote colorectal cancer proliferation and metastasis. J Transl Med. 2014; 12:109. PMC: 4020308. DOI: 10.1186/1479-5876-12-109. View

Thiery J, Acloque H, Huang R, Nieto M . Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5):871-90. DOI: 10.1016/j.cell.2009.11.007. View

Poggi A, Giuliani M . Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment. Vaccines (Basel). 2016; 4(4). PMC: 5192361. DOI: 10.3390/vaccines4040041. View

Wang S, Zhou J, Wang X, Hao J, Chen J, Zhang X . Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 2009; 219(1):114-22. DOI: 10.1002/path.2575. View

10.

Patani N, Jiang W, Mansel R, Newbold R, Mokbel K . The mRNA expression of SATB1 and SATB2 in human breast cancer. Cancer Cell Int. 2009; 9:18. PMC: 2731048. DOI: 10.1186/1475-2867-9-18. View

11.

Wu L, Chen J, Qin Y, Mo X, Huang M, Ru H . SATB2 suppresses gastric cancer cell proliferation and migration. Tumour Biol. 2015; 37(4):4597-602. DOI: 10.1007/s13277-015-4282-5. View

12.

Wei J, Shi Y, Zheng L, Zhou B, Inose H, Wang J . miR-34s inhibit osteoblast proliferation and differentiation in the mouse by targeting SATB2. J Cell Biol. 2012; 197(4):509-21. PMC: 3352956. DOI: 10.1083/jcb.201201057. View

13.

Britanova O, Akopov S, Lukyanov S, Gruss P, Tarabykin V . Novel transcription factor Satb2 interacts with matrix attachment region DNA elements in a tissue-specific manner and demonstrates cell-type-dependent expression in the developing mouse CNS. Eur J Neurosci. 2005; 21(3):658-68. DOI: 10.1111/j.1460-9568.2005.03897.x. View

14.

Mansour M, Asano E, Hyodo T, Akter K, Takahashi M, Hamaguchi M . Special AT-rich sequence-binding protein 2 suppresses invadopodia formation in HCT116 cells via palladin inhibition. Exp Cell Res. 2014; 332(1):78-88. DOI: 10.1016/j.yexcr.2014.12.003. View

15.

Fitzpatrick D, Carr I, McLaren L, Leek J, Wightman P, Williamson K . Identification of SATB2 as the cleft palate gene on 2q32-q33. Hum Mol Genet. 2003; 12(19):2491-501. DOI: 10.1093/hmg/ddg248. View

16.

Mansour M, Hyodo T, Akter K, Kokuryo T, Uehara K, Nagino M . SATB1 and SATB2 play opposing roles in c-Myc expression and progression of colorectal cancer. Oncotarget. 2015; 7(4):4993-5006. PMC: 4826260. DOI: 10.18632/oncotarget.6651. View

17.

Hua K, Wang M, Chen M, Wei L, Chen C, Ko C . The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis. Mol Cancer. 2014; 13:189. PMC: 4260797. DOI: 10.1186/1476-4598-13-189. View

18.

Mansour M, Hyodo T, Ito S, Kurita K, Kokuryo T, Uehara K . SATB2 suppresses the progression of colorectal cancer cells via inactivation of MEK5/ERK5 signaling. FEBS J. 2015; 282(8):1394-405. DOI: 10.1111/febs.13227. View

19.

Casciello F, Windloch K, Gannon F, Lee J . Functional Role of G9a Histone Methyltransferase in Cancer. Front Immunol. 2015; 6:487. PMC: 4585248. DOI: 10.3389/fimmu.2015.00487. View

20.

Yang M, Yu J, Chen N, Wang X, Liu X, Wang S . Elevated microRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2. PLoS One. 2014; 8(12):e85353. PMC: 3875556. DOI: 10.1371/journal.pone.0085353. View